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Abstract
Purpose Gestational diabetes mellitus (GDM) is one of the costly challenges in the health field. Despite the individual
studies in the Eastern Mediterranean, there is no comprehensive study in this regard. The aim of this study was to determine
the prevalence of GDM in the Eastern Mediterranean region.
Methods In this meta-analysis and systematic review, three international databases (PubMed, Web of science and Scopus)
were searched from inception until 30 December 2018. The Hui tool was used to assess the quality of the included studies.
Results Thirty-three studies performed on 887166 participants were included in the meta-analysis. Based on the results of
random effect method, the overall prevalence of GDM was 11.7%. Between six country with have three or more study,
pooled prevalence for Saudi Arabi it was 3.6 times more than Israel (17.6 vs. 4.9%), and for Pakistan, Qatar, Bahrain and
Iran were 15.3%, 14.7%, 12.2%, and 8.6%, respectively.
Conclusion Despite the high diversity of methods, the results of the present study indicate a high prevalence of GDM in the
Eastern Mediterranean region, indicating more policymakers’ interest in timely screening and proper management.
Keywords Epidemiology ● Gestational diabetes mellitus ● Eastern Mediterranean region ● Meta-analysis
Introduction
Gestational diabetes mellitus (GDM) is one of the challenges
of the health system in the world today. GDM is a type of
diabetes that has been diagnosed for the first time in preg-
nancy period that is characterized by glucose intolerance in
the second and third trimester of pregnancy in people who
have no previous history [1]. GDM, along with other types of
diabetes, is known as one of the most costly cases, which
annually imposes a cost of 1.2 trillion dollars worldwide and
expected to reach over 2.2 trillion dollars by 2030 [2]. One of
the major challenges in determining the exact prevalence of
GDM is the presence of more than eight criteria for its
diagnosis, which is provided by various organizations [3].
According to the latest figures in 2017, more than 18.6%
of women suffered from different types of hyperglycemia,
of whom 18.6 million were diagnosed with GDM [4]. The
prevalence of GDM is rising annually. The global pre-
valence of GDM varies from 1–28% in different regions of
the world based on the characteristics of the population
studied and the various diagnostic methods of GDM [5].
The Eastern Mediterranean region with the South Asian
region account for the highest prevalence of GDM [4].
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The most important risk factors of GDM are the history of
GDM, macrosomia, previous genetic anomalies, BMI > 25,
gestational hypertension, family history of diabetes, poly-
cystic ovary syndrome, history of abortion, and preterm labor
history [6]. GDM is associated with various maternal and
neonatal complications. The most frequent maternal compli-
cations of GDM on the basis of various WHO and IADPSG
criteria are include macrosomia, perinatal mortality, pre-
eclampsia, cesarean section, birth injury, shoulder dystocia,
neonatal hypoglycemia, and long-term metabolic complica-
tions for mother and fetus [7, 8]. There are individual studies
in this area, and so far, there has not been any comprehensive
study in the East Mediterranean despite being regarded as one
of the region of world with highest prevalence of GDM. On
the other hand, determining the exact prevalence of GDM will
help health policymakers to prioritize and plan for better
screening and control. This meta-analysis study was con-
ducted to determine the prevalence of GDM in the Eastern
Mediterranean region from 2000 to 2018.
Methods
Study design and eligibility criteria
The methods adopted for this systematic review have been
developed in accordance with the Cochrane Handbook for
Systematic Reviews and reported using Preferred Reporting
Items for Systematic Reviews and Meta-Analyses tool [9].
Descriptive, cohort, case-control studies included but reviews,
letter to editor, studies that did not allow access to the full text
version, and studies written in languages other than English
were excluded from the study. Only studies that were con-
ducted in EMRO region countries were included. Diagnosis
of GDM was based on the standards defined in the literature
[3]. The target population of the current study was
pregnant woman.
Search strategy
The International databases include PubMed, web of
science and Scopus were searched for relevant studies in
EMRO region limits in English language from inception
to 30 December 2018. The MEDLINE search strategy was
adopted to search in other databases. The specific search
strategies were created by a Health Sciences Librarian
with expertize in systematic review according to the
PRESS standard [10]. In addition, PROSPERO was used
to search for ongoing or recently completed systematic
reviews. Boolean operators (AND, OR, and NOT),
Medical Subject Headings (MeSH), truncation “*” and
related text words were used for search using the fol-
lowing keywords: “prevalence”, “Epidemiology”,
“gestational diabetes mellitus”, “GDM”, “hyperglycemia
in pregnancy”, and “gestational hyperglycemia” in East-
ern Mediterranean region countries.
Selection of studies and data extraction
According to the study protocol, two researchers indepen-
dently screened the titles and abstracts based on the elig-
ibility criteria, in next step, after removing duplicated
studies, studies full texts were screened based on the elig-
ibility criteria, and the required information was extracted.
Consensus method was used for solving controversies
among two researchers. Extracted data items included:
author, year of publication, country, sampling method,
design, diagnostic criteria of GDM, setting, gestational age,
Year of data collection, sample size, Age and Risk Factor,
Risk of bias, and prevalence of GDM.
Quality assessment
To assess the methodological quality and risk of bias,
each included observational study was evaluated by using
the Hoy et al tool. This 10-item tool evaluated the quality
of studies in two dimensions including external validity
(items 1–4 assess target population, sampling frame,
sampling method and nonresponse bias minimal) and
internal validity (items 5–9 assess data collection method,
case definition, study instrument, mode of data collection
and item 10 assesses bias related to the analysis). Risk of
bias was evaluated by two researchers independently,
disagreements were resolved via consensus method.
Data synthesis
All the eligible studies were included in the synthesis after a
systematic review. Data were combined with the forest plot.
The random-effects model was used for evaluation the
overall GDM. The heterogeneity of the preliminary studies
was evaluated with I2 tests. Subgroup analysis was con-
ducted to determine heterogeneity based on the country of
study conducted and diagnosis criteria of GDM. Meta-
analysis was performed using STATA 14 (StataCorp,
Texas, USA) statistical software.
Results
Overall results
Study selection
A total of 1166 articles from initial searches were retrieved
in three databases. Out of 772 nonduplicated studies in the
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title and abstract screening process, 394 studies were
excluded due to inappropriate titles. Out of 53 studies, 33
had eligibility criteria. Out of 20 excluded studies, eight
studies were review, two studies were letter to the editor,
three studies had no full text, and seven studies published in
non-English language (Fig. 1).
Study characteristics
Thirty three studies which were conducted on 887,166
participants in 11 countries of EMRO. The age range of
the participants was between 16 and 51 years. The mean
age of participants was 29.5 years. Studies were con-
ducted over the period 2000–2018. Geographically, most
studies were conducted in Iran (n= 10), Saudi Arabia (n
= 5), and Pakistan (n= 4). The most frequent sampling
method was census (N= 22). Descriptive studies made up
the largest number of studies (n= 32). The most common
GDM diagnostic criteria were Carpenter and Coustan (n
= 10) and ADA (N= 6). Most of the studies were con-
ducted in hospitals (n= 31). Studies were conducted on
pregnant women in their 24th to 40th gestational weeks.
Most of the studies included had low bias risk (n= 31)
(Table 1).
Main results
Prevalence of gestational diabetes mellitus
Gestational diabetes mellitus was reported in 33 studies and
was between 3.5 and 45.3% in the EMRO region. Pre-
valence of GDM in 27 studies reported based-on one
diagnostic criteria, and five and one study based-on two and
three criteria, respectively.
In 33 included study, 887,166 pregnant women assessed
for GDM and prevalence based on the diagnostic criteria
that reported the lowest and most positive cases (for studies
that diagnosis with more than one criterion) were 5.6%
(49,697 case) and 5.7% (50,646 case), respectively.
Based on the results of random effect method, the overall
prevalence of GDM in 49,697 and 50,646 positive reported
case were 10.7% (95% CI: 9.7, 11.6; I2= 99.6%) and
12.6% (95% CI: 11.6, 13.6; I2= 99.7%), respectively.
Based-on mean number of positive case (for studies that
diagnosis with more than one criterion), the overall pre-
valence of GDM in 50,178 case was 11.7% (95% CI: 10.7,
12.6; I2= 99.6%) (Fig. 2).
Subgroup analysis done for assessment of heterogeneity
base on country of study conducted and diagnosis criteria of
Fig. 1 Study selection process
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GDM. Included study in this systematic review conducted
in ten country, although Egypt, Morocco, Oman and Yemen
had only one study for each and prevalence of GDM was
24.2%, 15.6%, 10.0% and 5.1%, respectively. Between six
country with have three or more study, pooled prevalence
(based-on random model) for Saudi Arabi it was 3.6 times
more than Israel (17.6 vs. 4.9%), and for Pakistan, Qatar,
Bahrain and Iran were 15.3%, 14.7%, 12.2% and 8.6%,
respectively (Fig. 2).
GDM was diagnosis based-on eight criteria in included
study, which three criteria have only one study and of three
criteria, highest prevalence was for CDA (30.0%) in Saudi
Arabia. In five criteria (had four or more study), pooled
prevalence based-on IADPSG criteria was 4.5 times more
than Carpenter–Coustan (28.2 vs. 6.2%); and based-on
WHO, ADA and NDDG criteria were 15.2%, 10.3% and
8.1%, respectively (Table 2).
Meta-regression results
The results of random-effects meta-regression analyses,
publication year of study variable not significantly con-
tributed to heterogeneity with Coef.= 0.36% (95% CI:
−0.21, 0.93), Adj R-squared= 1.87%, P-Value= 0.210.
Also, there was a nonstatistically significant to explain
effect size variation by age mean (P-Value= 0.120) but had
direct correlation with Coef.= 0.89% (95% CI: −0.25,
0.20), Adj R-squared= 5.4% (Figs. 3, 4).
Discussion
Today, diabetes is one of the major threats to health
worldwide, according to World Health Organization
(WHO), diabetes was considered the eighth cause of death
in 2016 and will be the fourth cause of death in 2030 [11].
As far as the researcher knows, this is the first meta-
analysis study in the Eastern Mediterranean region. This
study was conducted to determine the prevalence of GDM
in the Middle East. A total of 33 studies completed on
887,166 people from 2000 to 2018 entered the final stage.
The prevalence of GDM in the Eastern Mediterranean
region is 11.7%, which is similar to previous review studies
conducted in Asia (11.5%) [6] and Eastern Mediterranean
(12.9%) [12], which could be due to similarity in demo-
graphic characteristics of some of the countries included in
review study in question.
Contrary to the present study, a lower prevalence of
GMD was reported in the developed countries such as
Germany (6.81%) [13], and USA (7.51%) [14]. Moreover,
the prevalence of GDM was higher developing countries,
China (14.8%) [15], India (10–19%) [16], Africa (13.9%)
[17], as compared to EMRO. This could be due to betterTa
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facilities, adequate screening for GDM in developed coun-
tries, large population, lower proportion of health facilities,
fewer health forces, poorer economic and social status in
developing countries, and also due to different diagnostic
criteria of GDM. Other factors that could cause this dif-
ference are the racial and ethnic difference in the population
of different continents, as studies have shown that the pre-
valence of GDM in the Asian race is more than African
Americans and European whites in the same age [18, 19].
The results also showed that the highest prevalence of
GDM was in Egypt (24.2%), Saudi Arabia (17.6%), and
Morocco (15.6%), which can be due to the methodological
differences between the studies included or due to factors
such as older age and higher BMI in these countries
[19, 20]. Based on the criteria used, the prevalence of GDM
was highly variable based on IADPSG (28.2%),
Carpenter–Coustan (6.2%), and WHO (15.2%), this sug-
gests that different methods have little agreement on the
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Fig. 2 Forest plot, pooled analyses, and subgroup analyses by country for estimation the gestational diabetes mellitus prevalence in the EMRO
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Table 2 Prevalence of gestational diabetes mellitus based on different diagnostic criteria in EMRO
Diagnostic criteria First author (year) Country Screening test ES* 95% CI for ES % Weight
• IADPSG
Utz (2018) [50] Morocco OGTT (75 g) 15.6 14.0, 17.3 20.2
Hosseini (2018) [36] Iran OGTT (100 g, 3 h) 9.3 7.4, 11.5 20.1
Shahbazian (2016) [47] Iran OGTT (75 g) 29.9 26.6, 33.3 20.0
Alfadhli (2015) [21] Saudi Arabia OGTT (75 g, 2 h) 41.5 35.7, 47.6 19.6
Agarwal (2015) [26] Saudi Arabia OGTT 45.3 43.2, 47.3 20.1
Overall random pooled ES (I2= 99.5%) 28.2 13.4, 43.0 100.0
• WHO
Riaz (2018) [44] Pakistan OGTT (75 g) 10.2 9.7, 10.8 13.0
Ali (2018) [30] Pakistan OGTT 10 6.2, 15 11.9
Bashir (2018) [23] Qatar OGTT (75 g, 2 h) 21.4 19.7, 23.3 12.8
Wahabi (2017) [51] Egypt OGTT (75 g) 24.2 23.4, 25.1 12.9
Abu-Heija (2015) [25] Oman OGTT (75 g, 2 h) 10 9.2, 10.8 12.9
Ahsen (2014) [27] Pakistan OGTT 17 12.1, 22.9 11.3
Bener (2011) [33] Qatar OGTT (75 g, 2 h) 16.3 14.5, 18.2 12.8
Al-Rowaily (2010) [32] Saudi Arabia OGTT (75 g, 2 h) 12.5 10.0, 15.3 12.5
Overall random pooled ES (I2= 99.2%) 15.2 10.4, 20.1 100.0
• ADA
Abdelmola (2017) [24] Saudi Arabia OGTT (100 g, 3 h) 8.2 5.8, 11.1 10.9
Ali (2016) [29] Yemen OGTT 5.1 3.0, 8.2 11.0
Alfadhli (2015) [21] Saudi Arabia OGTT (75 g, 2 h) 17 12.7, 21.9 9.8
Agarwal (2015) [26] Saudi Arabia OGTT 13.3 12.0, 14.8 11.4
Wahabi (2013) [52] Saudi Arabia OGTT (100 g, 3 h) 18.7 17.3, 20.1 11.4
Al-Kuwari (2011) [31] Qatar OGTT (100 g, 3 h) 6.4 5.7, 7.2 11.5
Al-Rowaily (2010) [32] Saudi Arabia OGTT (75 g, 2 h) 3.8 2.4, 5.6 11.4
Shirazian (2008) [48] Iran OGTT (75 g, 2 h) 7.4 5.8, 9.2 11.3
Rajab (2003) [43] Bahrain OGTT (75 g) 13.6 11.9, 15.3 11.3
Overall random pooled ES (I2= 97.9%) 10.3 6.8, 13.8 100.0
• NDDG
Rajab (2012) [42] Bahrain OGTT 10.1 9.8, 10.3 25.9
Hossein-Nezhad (2007) [37] Iran OGTT (100 g, 3 h) 4.0 3.2, 4.8 25.7
Hadaegh (2005) [35] Iran OGTT (100 g, 3 h) 6.3 4.6, 8.3 24.6
Ardawi (2000) [22] Saudi Arabia OGTT (100 g, 2 h) 12.5 10.3, 14.9 23.9
Overall random pooled ES (I2= 98.7%) 8.1 4.2, 12.0 100.0
• Carpenter–Coustan
Hosseini (2018) [36] Iran OGTT (100 g, 3 h) 4.2 2.9, 5.8 8.9
Momenzadeh (2015) [41] Iran OGTT (100 g, 3 h) 3.5 2.8, 4.4 9.9
Bibi (2015) [34] Pakistan OGTT (100 g, 3 h) 26.3 20.2, 33.2 2.1
Mohammadzadeh (2015) [40] Iran OGTT (100 g, 3 h) 4.9 3.7, 6.2 9.3
Manafi (2013) [39] Iran OGTT (100 g, 3 h) 9.6 6.2, 13.9 4.4
Sella (2013) [45] Israel OGTT (100 g) 3.9 3.8, 4.0 10.6
Al-Kuwari (2011) [31] Qatar OGTT (100 g, 3 h) 6.4 5.7, 7.2 10.1
Sella (2011) [46] Israel OGTT (100 g) 6.1 6.0, 6.2 10.6
Soheilykhah (2010) [49] Iran OGTT (100 g) 10.3 8.5, 12.2 7.9
Hossein-Nezhad (2007) [37] Iran OGTT (100 g, 3 h) 4.7 3.9, 5.6 9.9
Hadaegh (2005) [35] Iran OGTT (100 g, 3 h) 8.9 6.9, 11.2 7.2
Keshavarz (2005) [38] Iran OGTT (100 g, 3 h) 4.8 3.7, 6.1 9.3
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diagnosis of a certain degree of GDM that can be explained
by the fact that they were created for a specific purpose and
evaluated in different populations. Another challenge was
the one step and two step approach for GDM screening. The
diverse prevalence of GDM based on the geographical areas
of the EMRO, various methods of measuring GDM in
different countries are an important barrier to establishing a
coordinated and similar screening program in the region.
The highest prevalence was obtained by the IADPSG
method, which was similar to a review study carried out in
India [21]. This could be due to the low threshold for fasting
blood glucose in this method, which is at a low level;
although IADPSG has gained popularity in recent years
considering its lower costs and better responses and
improvements in pregnancy outcomes in mothers [22, 23].
One of the main challenges in determining the correct
prevalence rate is various GDM diagnostic methods in
different areas that must be taken into consideration.
Limitations and strengths
1. A limitation was the unequal number of studies in dif-
ferent countries and lack of study in many of them. 2. The
more of included studies were descriptive in nature, which
have their own specific methodological limitations. 3. Only
English articles that were published in valid journals were
included, so, articles that were published in other languages
were not entered, and 4. Some studies have not provided
detailed information on their methodology and GDM
measurement procedure and thus attempts were made to
contact their authors to obtain the relevant information. The
strength of this study was that to the researchers’ knowl-
edge, this is the first meta-analysis carried out in the Eastern
Mediterranean region on the prevalence of GDM. Also, to
minimize the risk of bias, all steps were completed by two
researchers. Despite achieving the main aim of the study but
according the high prevalence of GDM, factors which may
influence the prevalence of GMD were not evaluated in the
included studies. As an important limitation, most studies
did not evaluate the effects of GDM on the outcomes of
mothers and fetuses. In addition, differences in the out-
comes due to differences in GDM measurement methods
were not examined. The imposed costs based on GDM
assessment methods were not also evaluated in the non-
enrolled studies.
Table 2 (continued)
Diagnostic criteria First author (year) Country Screening test ES* 95% CI for ES % Weight
Overall random pooled ES (I2= 99.2%) 6.2 5.2, 7.2 100.0
• CDA
Agarwa (2015) [26] Saudi Arabia OGTT 30.0 28.2, 31.9 100.0
• ACOG
Zamstein (2018) [53] Israel OGTT (100 g) 4.7 4.6, 4.8 100.0
• Other*
Al Mahroos (2005) [28] Bahrain OGTT (75 g, 3 h) 13.3 12.6, 13.9 100.0
*ES: Effect size; other: Fourth international workshop–conference on gestational diabetes
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Fig. 3 Meta-regression between publication year of study and the
prevalence of gestational diabetes mellitus in EMRO
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Fig. 4 Meta-regression between mean age of participants and the
prevalence of gestational diabetes mellitus in EMRO
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Conclusion
Despite the high diversity of methods, the results of this
study indicate a high prevalence of GDM in the Eastern
Mediterranean region, indicating more policymakers’
interest in timely screening and proper management of such
disease. Regarding increasing prevalence rate, imposition of
high costs on the health system, and adverse outcomes on
mother and infants, one of the most significant research
points in order to achieve a systematic and cost-effective
approach based on the characteristics of the countries of the
region for measuring, training, preventing, and controlling
GDM in the region. It seem crucial for policymakers to take
measures regarding raising the awareness of pregnant
women, families during fertility about GDM warning signs.
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